#1 Clinical Trials Search in Europe

Eo2317

This article explores the ongoing clinical trials of EO4010, a groundbreaking cancer vaccine therapy being tested in combination with other drugs for patients with previously treated metastatic colorectal cancer. The study aims to evaluate the safety, tolerability, and effectiveness of this innovative treatment approach in improving outcomes for patients with advanced colorectal cancer.

Table of Contents

What is EO2317?

EO2317 is a new type of cancer treatment called a therapeutic vaccine. It is being studied as part of a combination therapy for patients with metastatic colorectal cancer who have already received other treatments[1]. EO2317 is one of the active components in a vaccine called EO4010, which is being tested in clinical trials.

This vaccine is different from preventive vaccines that protect against diseases. Instead, EO2317 is designed to help treat cancer that has already developed and spread to other parts of the body.

How does EO2317 work?

EO2317 works by stimulating the body’s immune system to fight cancer cells. It is a microbial-derived peptide, which means it’s a small protein fragment derived from microorganisms[1]. The vaccine is designed to:

  • Help the immune system recognize and attack specific proteins (called tumor-associated antigens or TAAs) that are found on cancer cells
  • Increase the number and activity of immune cells (specifically T cells) that can fight the cancer
  • Work together with other cancer treatments to improve their effectiveness

Who is EO2317 for?

The current clinical trial is testing EO2317 (as part of the EO4010 vaccine) in patients with:

  • Metastatic colorectal cancer: This means colorectal cancer that has spread from the colon or rectum to other parts of the body
  • Cancer that cannot be surgically removed
  • Cancer that has been previously treated with standard therapies
  • A specific genetic profile (HLA-A2 positive)
Patients must also meet other criteria, such as being at least 18 years old and having a good overall health status[1].

Clinical Trial Details

The clinical trial for EO2317 (as part of EO4010) is called the “AUDREY” study. It is a global, multicenter Phase 1/2 trial. Here are some key points about the trial:

  • The vaccine is being tested in combination with other cancer treatments, including nivolumab (an immunotherapy drug) and bevacizumab (a drug that targets blood vessel growth in tumors)
  • The trial is divided into different groups (cohorts) to test various combinations and doses of the treatments
  • Patients receive regular scheduled visits to get the study treatment and undergo various tests and procedures
  • The main goal is to evaluate the safety and effectiveness of the treatment combination

Potential Benefits

While it’s important to note that the effectiveness of EO2317 is still being studied, the researchers hope to see benefits such as:

  • Shrinking of tumors or slowing of tumor growth
  • Longer time before the cancer progresses
  • Improved overall survival
  • A new treatment option for patients who have already tried standard therapies
The study will measure these outcomes using various methods, including imaging scans and blood tests[1].

Safety and Side Effects

A primary goal of the clinical trial is to assess the safety of EO2317 when used in combination with other treatments. The researchers will carefully monitor patients for any side effects or adverse reactions. Common side effects of cancer vaccines may include:

  • Injection site reactions (redness, swelling, or pain)
  • Flu-like symptoms (fever, chills, fatigue)
  • Nausea or vomiting
It’s important to note that as this is a new treatment, there may be unknown side effects. Patients in the trial will be closely monitored and should report any unusual symptoms to their healthcare team[1].

Aspect Details
Study Drug EO4010 (novel microbial-derived peptide therapeutic vaccine)
Combination Therapies Nivolumab and/or Bevacizumab
Target Population HLA-A2 positive patients with previously treated metastatic colorectal cancer
Primary Objective Evaluate safety and tolerability of EO4010 in combination with other drugs
Secondary Objectives Assess immunogenicity, tumor response rates, progression-free survival, overall survival
Study Design Global multicenter phase 1/2 trial with multiple cohorts
Treatment Duration Expected to be completed by week 43, with follow-up visits

FAQ

  • What is EO4010 and how does it work? EO4010 is a novel microbial-derived peptide therapeutic vaccine designed to stimulate the immune system to fight against colorectal cancer cells. It works by targeting specific proteins found on cancer cells, potentially helping the body's immune system to recognize and attack these cells more effectively.
  • Who is eligible for this clinical trial? The trial is open to HLA-A2 positive patients with advanced non-resectable colorectal adenocarcinoma who have been previously treated with standard therapies or are not considered candidates for such treatments. Patients must be 18 years or older and have an ECOG performance status of 0 to 1.
  • What other drugs are being used in combination with EO4010? EO4010 is being tested in combination with nivolumab (an immune checkpoint inhibitor) and/or bevacizumab (an anti-angiogenic drug). Different combinations are being evaluated in different cohorts of the study.
  • What are the main objectives of this clinical trial? The primary objective is to evaluate the safety and tolerability of EO4010 in combination with nivolumab and/or bevacizumab. Secondary objectives include assessing the immune response, measuring tumor response rates, and evaluating progression-free and overall survival.
  • How long does the treatment phase of the trial last? The treatment phase is expected to be completed by week 43. Patients will continue receiving the study treatment as long as they benefit from it, unless their disease worsens, they decide to stop, or the study ends.

Ongoing Clinical Trials on Eo2317

  • Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Spain

Glossary

  • Metastatic colorectal cancer: Cancer that has spread from the colon or rectum to other parts of the body.
  • EO4010: A novel microbial-derived peptide therapeutic vaccine being tested for the treatment of metastatic colorectal cancer.
  • Nivolumab: An immune checkpoint inhibitor drug that helps the immune system fight cancer cells.
  • Bevacizumab: An anti-angiogenic drug that helps prevent the growth of blood vessels that supply tumors.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) that is important for the immune system's ability to recognize and respond to the vaccine.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects their daily living abilities.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • T cells: A type of white blood cell that plays a central role in the immune response against cancer.
  • Tumor associated antigens (TAAs): Proteins found on cancer cells that can be recognized by the immune system.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.

References

  1. http://clinicaltrials.eu/trial/study-on-eo4010-vaccine-with-nivolumab-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer-who-have-already-received-treatment/